Nope go back and listen to their CC, the 70% deadline was tied to their year end not calendar year end. Their fiscal ends March 2015...
That was my point Arena has nothing to do with marketing.. Sitting here bashing management over sales and marketing results is pointless. Arena has only one thing to do these days. Make Belviq, and expand the pipeline and other Belviq indications... They have no marketing responsibility and any success for increase in sales and market penetration is all on Eisai.
Common hedge, if a company has 2 million shares outstanding and we have another 1 million shares shorted we have 3 million longs. That is 150% of the float, yes the additional 1 million shares are now borrowed and owed back as some point.. Shorting creates more shares out of thin air impacting supply and demand... Instead of having to pay up to get longs to sell, they only need to buy shorted shares...
I am happy with a 5% increase in ownership during a time when the price was under pressure, over a decrease in ownership.
over 5 months ahead of schedule and ahead of guidance. How about giving them a thumbs up for blowing out that guidance over and over. Insurance coverage will be closer to 80% by their 70% deadline maybe even higher...
Or, you can keep posting FUD and personal attacks on Arena management.
Make it a great day.
In the short run a stocks price is a popularity contest, but in the long run it is a voting machine.
Institutional ownership now at 49.15% a nice pop up from the 46% area... Looks like they were buying into all that shorting...
Why admit you are wrong when you can make money proving you were right, by skating the rules and manipulating the stock price down. They were wrong on their bet against Belviq being approved, however, they have been successful and right about Arenas stock price. The successfully drove new buyers away and got some longs to jump ship taking this down to low 3's to times.
Went on a cruise and was gone for 10 days. Wife said no internet, no phones, NO BUSINESS. Happy wife, happy life.
for a week so I missed both the 11/7/14 and the 11/14/14..
Cleary you have not talked with anyone of significance at Eisai. They are executing theit strategy and moving forward.
Unfortunately I am in this dog for awhile longer. Three management teams later and we still can't get folks to execute. From 5 hospitals to 17 that is only one per week, they should be able to do that with word of mouth and no sales team. Have not managed the Phase II well and now we are pushed back. We will get there but I fear by the time we get to the finish line we will have a much smaller percentage at an even lower price. Dilution is a necessary evil when you don't hit your timeline and milestones.
From 5 hospitals that are exclusive to 17, that does not seem like much when you consider they had a year to prime the pump and did not need a large sales force, because the market was small and concentrated. That is only 1 hospital per week, how many sales people do they have?
I likes how the commentator teed up the question for him to knock it out of the park. Bio Tech companies are priced based on their potential market and future. Your price has gone from 11 to 4 bucks a share why is Wall Street not pricing in the enormous market potential of your drug. ( paraphrased )....
Tweeeet Tweeeeet Strike 3 !!!!!! There is no excuse for not knowing your drug and the market stats enough to be able to have 5 canned answers that are within your attorneys guidelines to address most questions in a positive and exciting way. To get people excited about the size of the market, the potential of the market. We have 100,000,000 obese in America and 42 million adult smokers. If we just get 1 million from each group to take Belviq that is 24,000,000 scripts per year. and that is only 1% of the obese market and 3% of the smoking market. These numbers tell me that Wall Street is not paying attention to what the real potential is..
We got the smoking results as well as the Bel Phen primary and secondary end points with further information to be released on Thursday. While everyone was hoping for this and wishing for it, it was an unknown.
We now know 60,000 doctors have scripted Belviq since launch. That is a lot of doctors that have decided to give it a try. When you consider that at launch only 1 out of 13 doctors were not going to script Belviq since it was new and wanted to wait and see how well the real world results were after a year, that is good news... Doctors adopting Belviq as part of their treatment strategy is very positive for the future of Belviq.
During the off season when the industry was flat we managed to increase our scripts 30% and take market share.
I could go on.. but I won't... Have a great night.
Those are the small details Wall Street and Main Street are missing. Now with safety results in and efficacy increased with the combo of Bel and Phen, I think it is reasonable to expect some of the doctors scripting Phen alone will start to dip their toes in the Belviq pool.